{"id":"W149751534","doi":"10.1182/blood.v122.21.1809.1809","title":"Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Brentuximab vedotin; Medicine; Internal medicine; Anaplastic large-cell lymphoma; Oncology; Population; Phases of clinical research; Antibody-drug conjugate; Refractory (planetary science); CD30; Lymphoma; Surgery; Clinical trial; Immunology; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003033919,0.000973766,0.001842465,0.0004118477,0.0004580312,0.0009367829,0.0006107865,0.0009393562,0.002023048],"category_scores_gemma":[0.001224499,0.0003145513,0.001327931,0.0003434218,0.0005601101,0.0007532609,0.0005294437,0.001966025,0.0005332238],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007908658,"about_ca_system_score_gemma":0.0007372522,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006722042,"about_ca_topic_score_gemma":0.0009942377,"domain_scores_codex":[0.999247,0.0003632582,0.00004272912,0.0001449758,0.00008788182,0.0001141986],"domain_scores_gemma":[0.9987686,0.0002245729,0.0002284547,0.00009933918,0.00008736605,0.0005915457],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6681023,0.06036302,0.08108935,0.0009875656,0.004452765,0.0007423077,0.0006528929,0.005510511,0.03689857,0.0001858044,0.005369202,0.1356458],"study_design_scores_gemma":[0.201514,0.6355183,0.1477779,0.00007094208,0.002614292,0.0006949861,0.0001918509,0.003181431,0.004133824,0.0002826744,0.003957052,0.00006288885],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957461,0.001645587,0.000282442,0.0001457138,0.00003973985,0.000547957,0.0008733036,0.00003013097,0.0006889619],"genre_scores_gemma":[0.9932847,0.0009643081,0.0004775538,0.0004021398,0.00009147512,0.0008345037,0.003114459,0.00001192205,0.0008188817],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003033919,"threshold_uncertainty_score":0.01604509,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01172892226341644,"score_gpt":0.2426924262607855,"score_spread":0.2309635039973691,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}